



PAXMAN
UK CLINICAL
STUDY OF EFFICACY



UK observational study reports an 89% success rate following use of the Paxman system in breast cancer patients, with only 11% with severe hair loss requiring wigs.

EVALUATION OF HAIR LOSS (ALL PATIENTS)



Results


Alopecia prevention.

- Of patients receiving chemotherapy (n=95), grade 3 hair loss was observed in 5 patients and grade 4 hair loss in one patient (only 11% of patients required wigs).
- 5 out of 95 patients discontinued scalp cooling treatment.
- Of patients receiving FEC specifically (n=62), grade 3 hair loss was observed in 2 patients and grade 4 hair loss in one patient (only 13% of patients required wigs).

Patients

Patients reported high comfort and acceptability levels with low numbers of withdrawals from scalp cooling.

EVALUATION OF HAIR LOSS (FEC PATIENTS)



- 85% of patients reported that they were comfortable, reasonably comfortable, or very comfortable during the scalp cooling period.
- 12% of patients reported they were uncomfortable with an additional 3% very uncomfortable.
- Only 5% of patients discontinued scalp cooling before the end of chemotherapy treatment, with discontinuation because of discomfort seen in one patient.
- Headaches at some time during treatment cycles were reported in 32% of patients.




Methods

- 95 breast cancer patients being treated with chemotherapy in the adjuvant or palliative setting¹.
- Open, non-randomised, observational study conducted at 8 UK sites between 1997-2000.
- **Chemotherapy regimens include:**
 - Epirubicin (60-75 mg/m²) regimens as monotherapy (10 patients) or the FEC combination therapy regimen used 1997-2000 (62 patients).
 - Doxorubicin as monotherapy or combination administered to 11 patients (doses ranging from 30-60 mg/m²).
 - Docetaxel single agent (75-100 mg/m²) (n=5) CMF** (n=5).

Scalp cooling times:

- Pre-infusion cooling time of 15-20 minutes.
- Cooling was maintained during the infusion period.
- Post-infusion cooling time of 120 minutes for majority of patients.

Hair loss graded according to criteria:



Patient age range 28-61 years, mean age 44.

Patients completed questionnaires related to comfort and acceptability of scalp cooling.

89%

success rate in breast cancer patients following use of the Paxman system.

Massey CS. A multi-centre study to determine the efficacy and patient acceptability of the Paxman Scalp Cooling System to prevent hair loss in patients receiving chemotherapy. Eur J Oncol Nursing; 8: 121-130,2004.



PAXMAN^o
PIONEERS IN SCALP COOLING